Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Gracell Closes Cell Therapy Deal with Seagen; No Details Released

publication date: Mar 17, 2023

Gracell Biotech, a Shanghai cell/gene therapy company, announced in a press release that it had entered an unusual, non-exclusive global deal with Seattle’s Seagen to conduct pre-clinical research on Seagen’s cell therapy products and acquire (non-exclusive) rights to five of Seagen’s cell therapies. The press release was dated March 8, 2023, before Seagen announced it would be acquired by Pfizer for $43 billion. Neither Gracell nor Seagen have issued a press release explaining the agreement, though Seagen has the excuse of a $43 billion sale that required its full attention. More details....

Stock Symbol: (NSDQ: GRCL)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital